Technical analysis of MediciNova, Inc. (MNOV): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions.
Price Performance
| 1 month | +88.06% |
| 3 months | +90.91% |
| Year-to-date | +92.37% |
| 1 year | +106.56% |
| 3 years | +17.21% |
| 5 years | -35.71% |
52-Week Range
| 52-week High | $2.62 |
| 52-week Low | $1.17 |
| Avg Volume (90d) | 65K |
Technical Indicators
| SMA 50 | $1.46 |
| SMA 200 | $1.45 |
| Beta | 0.61 |
| 30-day Volatility (annualised) | 83.7% |
| Price vs SMA 50 | +72.9% |
| Price vs SMA 200 | +74.4% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.66 | |
| 2025-11 | $1.45 | -12.7% |
| 2025-12 | $1.31 | -9.7% |
| 2026-01 | $1.72 | +31.3% |
| 2026-02 | $1.45 | -15.7% |
| 2026-03 | $1.37 | -5.5% |
| 2026-04 | $1.39 | +1.5% |
| 2026-05 | $1.36 | -2.2% |
| 2026-06 | $1.32 | -2.9% |
| 2026-07 | $1.33 | +0.8% |
| 2026-08 | $1.44 | +8.3% |
| 2026-09 | $2.52 | +75.0% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $2.52 |
| Market Cap | $124M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.65 |
| EV / EBITDA | -5.72 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 8.75 |